Antinociceptive effects of monoamine reuptake inhibitors administered alone or in combination with mu opioid agonists in rhesus monkeys

1998 ◽  
Vol 135 (1) ◽  
pp. 99-106 ◽  
Author(s):  
Michael B. Gatch ◽  
S. Stevens Negus ◽  
Nancy K. Mello
Keyword(s):  
Rhesus Monkeys ◽  
Mu Opioid ◽  
Opioid Agonists ◽  
Antinociceptive Effects ◽  
Monoamine Reuptake Inhibitors

scholarly journals Interaction between Mu and Delta Opioid Receptor Agonists in an Assay of Capsaicin-Induced Thermal Allodynia in Rhesus Monkeys

2012 ◽  
Vol 2012 ◽  
pp. 1-8 ◽  
Author(s):  
S. Stevens Negus ◽  
Ember M. Morrissey ◽  
John E. Folk ◽  
Kenner C. Rice
Keyword(s):  
Rhesus Monkeys ◽  
Delta Opioid Receptor ◽  
Preclinical Models ◽  
Thermal Nociception ◽  
Mu Opioid ◽  
Opioid Agonists ◽  
Antinociceptive Effects ◽  
Mu Agonists ◽  
Opioid Receptor Agonists ◽  
Dose Dependent

Delta opioid agonists enhance antinociceptive effects of mu-opioid agonists in many preclinical assays of acute nociception, but delta/mu interactions in preclinical models of inflammation-associated pain have not been examined. This study examined interactions between the delta agonist SNC80 [(+)-4-[(αR)-α-((2S,5R)-4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide] and the mu agonist analgesics methadone, morphine, and nalbuphine in an assay of capsaicin-induced thermal allodynia in rhesus monkeys. Thermal allodynia was produced by topical application of capsaicin to the tail. Antiallodynic effects of methadone, morphine, and nalbuphine were evaluated alone or in combination with fixed proportions of SNC80 identical to proportions previously shown to enhance acute thermal antinociceptive effects of these mu agonists in rhesus monkeys (0.9 : 1 SNC80/methadone; 0.29 : 1 SNC80/morphine; 3.6 : 1 SNC80/nalbuphine). Methadone, morphine, and nalbuphine each produced dose-dependent antiallodynia. SNC80 produced partial antiallodynia up to the highest dose tested (5.6 mg/kg). SNC80 produced a modest, enantioselective, and naltrindole-reversible enhancement of methadone-induced antiallodynia. However, SNC80 did not enhance morphine antiallodynia and only weakly enhanced nalbuphine antiallodynia. Overall, SNC80 produced modest or no enhancement of the antiallodynic effects of the three mu agonists evaluated. These results suggest that delta agonist-induced enhancement of mu agonist antiallodynia may be weaker and less reliable than previously demonstrated enhancement of mu agonist acute thermal nociception.

Comparison of Antinociceptive Effects Induced by Kappa Opioid Agonists in Male and Female Mice

Analgesia ◽  
1999 ◽  
Vol 4 (3) ◽  
pp. 397-404 ◽  
Author(s):  
Corinne A. Patrick ◽  
M. C. Holden Ko ◽  
James H. Woods
Keyword(s):  
Kappa Opioid ◽  
Male And Female ◽  
Female Mice ◽  
Opioid Agonists ◽  
Antinociceptive Effects

scholarly journals Pyrrolo- and pyridomorphinans: Non-selective opioid antagonists and delta opioid agonists/mu opioid partial agonists

2014 ◽  
Vol 22 (15) ◽  
pp. 4067-4072 ◽  
Author(s):  
V. Kumar ◽  
M.J. Clark ◽  
J.R. Traynor ◽  
J.W. Lewis ◽  
S.M. Husbands
Keyword(s):  
Opioid Antagonists ◽  
Mu Opioid ◽  
Partial Agonists ◽  
Opioid Agonists

Some effects of putative G-protein biased mu-opioid receptor agonists in male rhesus monkeys

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Jeremy C. Cornelissen ◽  
Bruce E. Blough ◽  
Laura M. Bohn ◽  
S. Stevens Negus ◽  
Matthew L. Banks
Keyword(s):  
G Protein ◽  
Opioid Receptor ◽  
Rhesus Monkeys ◽  
Mu Opioid Receptor ◽  
Mu Opioid ◽  
Receptor Agonists ◽  
Opioid Receptor Agonists ◽  
Male Rhesus

scholarly journals Perioperative Management of Buprenorphine: Solving the Conundrum

Pain Medicine ◽  
2018 ◽  
Vol 20 (7) ◽  
pp. 1395-1408 ◽  
Author(s):  
Aurora Naa-Afoley Quaye ◽  
Yi Zhang
Keyword(s):  
Perioperative Management ◽  
Case Reports ◽  
Management Strategies ◽  
Case Series ◽  
Analgesic Efficacy ◽  
Published Data ◽  
Opioid Use ◽  
Mu Opioid ◽  
Periprocedural Management ◽  
Opioid Agonists

Abstract Objective There is no consensus on the optimal perioperative management of patients on buprenorphine (BUP) for opioid use disorder (OUD). This article will review the available literature on BUP and the analgesic efficacy of BUP combined with full mu-opioid agonists and discuss the conflicting management strategies in the context of acute pain and our institution’s protocol for the periprocedural management of BUP. Methods We searched published data on BUP periprocedural management from inception through March 2018 without language restrictions. Study selection included publications reporting outcomes on perioperative pain management in OUD patients maintained on BUP. Results Our search resulted in four case reports supporting periprocedural discontinuation of BUP and two case series, one secondary observational study, one prospective matched cohort study, and four retrospective cohort studies supporting periprocedural continuation of BUP. No clinical trials were identified. Conclusions Maintaining BUP perioperatively does not lead to worsened clinical outcomes. Patients can receive adequate pain control from mu-opioid agonists while maintained on BUP. Based upon available evidence, we recommend continuing BUP at a reduced dose when indicated to avoid withdrawal symptoms and to facilitate the analgesic efficacy of mu-opioid agonists administered in combination for acute postoperative pain.

scholarly journals Effects of stimulation of mu opioid and nociceptin/orphanin FQ peptide (NOP) receptors on alcohol drinking in rhesus monkeys

2019 ◽  
Vol 44 (8) ◽  
pp. 1476-1484 ◽  
Author(s):  
Shawn M. Flynn ◽  
Phillip M. Epperly ◽  
April T. Davenport ◽  
Gerta Cami-Kobeci ◽  
Stephen M. Husbands ◽  
...  
Keyword(s):  
Alcohol Drinking ◽  
Rhesus Monkeys ◽  
Orphanin Fq ◽  
Mu Opioid ◽  
Nop Receptors ◽  
Stimulation Of
Sign in / Sign up

Export Citation Format

Share Document